For a long time, the cure for diabetes type 1 and type 2 has relied on agonizing insulin shots for patients or insulin infusion via mechanical pumps. Regarding this, experts have been creating artificial pancreatic beta cells with the he…
According to the statistics of International Diabetes Federation (IDF), in 2013, the prevalence of diabetes among adults aged from 20 to 79 was 8.3% and the number of diabetes patients has reached 382 million in the world, 80% of which come from middle income and low income countries and the figure demonstrates a fast rising trend. It is estimated that by 2035, there will be nearly 592 million people suffering from diabetes in the whole world. The number of diabetes patients in China was estimated to be 98.4 million in 2013, ranking first in the world, followed by India (65.1 million), USA (24.4 million), Brazil (11.9 million) and Russia (10.9 million). IDF estimates that by 2035, the number of diabetes patients in China will reach 143 million, still ranking first in the world while that in America will reach 29.7 million. The fast growth of diabetes in China and other developing countries has put a heavy burden on their social and economic development.
As one of the earliest oral antidiabetic drugs, sulfonylurea is common to patients with insulin hyposecretion. By stimulating insulin secretion, sulfonylurea is able to reduce blood glucose. According to the length of action, sulfonylurea can be categorized into short-acting, medium-acting and long-acting preparations. And glibenclamide, gliquidone, gliclazide and glimepiride are the common drugs in the class of sulfonylurea.
Developed by Boehringer-Ingelheim, gliquidone first came into the German market in 1975 under the trade name of Glurenorm. As the main metabolite of gliquidone is eliminated from body with bile and only 5% is excreted renally, i.e. hardly influenced by glomerular filtration rate (GFR), drug metabolism can ease kidney’s burden and therefore more suitable for patients with damaged renal function. Gliguidone is with good tolerance and few side effects for common patients and few, if any, patients will have skin allergy, gastrointestinal discomfort and sensation of vertigo. If guiguidone alone doesn’t work, metformin could be added in the treatment.
As gliquidone is expelled from the body with bile after being metabolized by CYP3A4 enzyme system in the liver and only 6% of it is excreted through kidney, it is more suitable for patients with kidney disorders.
In 1990, gliquidone co-produced by Boehringer-Ingelheim and Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd entered China under the trade name of Glurenorm. And in 1997, gliquidone developed by TIPR Pharmaceutical Responsible Co., Ltd came into the market under the trade name of Jieshi. Apart from the above-mentioned two products, other products are also available in the Chinese market.
According to CRI’s market survey, in 2014, Beijing Wanhui Double-Crane Pharmaceutical Co., Ltd took up a market share of about 97% for sales value in China while other companies like TIPR Pharmaceutical Responsible Co., Ltd, Jiangsu Vanguard Pharmaceutical Co., Ltd and Jilin Jinheng Pharmaceutical Co., Ltd and Shijiazhuang Yiling Pharmaceutical Co., Ltd shared the rest market share. The annual sales value of gliquidone in sample hospitals stays at CNY 40 million in recent years.
Readers can get at least the following information through this report:
- market size of gliquidone in China
- major manufacturers of gliquidone for Chinese market and their market share
- retail price of gliquidone in Chinese market
- market outlook of gliquidone in China
The author suggests the following groups of people purchase this report:
- manufacturers of antidiabetic drugs
- investors/ research institutions interested in Chinese medicine market
- any interest in the medicine market, please contact CRI for customized survey service